Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors (MMF)

• ClinicalTrials.gov Identifier: NCT03971591
• Recruitment Status: Recruiting
• First Posted: June 3, 2019
• Last Update Posted: October 13, 2022
• Sponsor: Medical College of Wisconsin
• Collaborators: Loyola University Chicago; Marquette University; University of Illinois at Chicago
• Information provided by (Responsible Party): Melinda Stolley, Medical College of Wisconsin

Study Description

Brief Summary:

This study will examine the efficacy of Men Moving Forward (MMF), a four-month community-based lifestyle intervention designed for AA PC survivors. MMF is rooted in the evidence-based Moving Forward lifestyle intervention developed with and for AA breast cancer survivors. This intervention was adapted in collaboration with AA PC survivors. It will offer twice weekly sessions aimed at supporting adherence to the ACS nutrition and physical activity guidelines to promote improved body composition (i.e., decreased adiposity, increased lean mass).

Condition or disease	Intervention/treatment	Phase
Prostate Cancer	Behavioral: Immediate Guided Lifestyle Program Intervention	Not Applicable

Detailed Description:

Aim 1. To examine the efficacy of the Men Moving Forward guided intervention, as compared to a self-guided control intervention, in producing significant post-intervention changes in body composition in 200 AA PC survivors.

Hypothesis: Men randomized to the guided arm will exhibit significant post-intervention decreases in adiposity and increases in lean body mass compared to men randomized to the control arm.

Aim 2. To investigate the effects of participation in the Men Moving Forward guided intervention on health behaviors and quality of life outcomes.

Hypothesis: Men in the guided program will exhibit increased intake of fruits and vegetables and decreased intake of red meat/processed meat, greater levels of physical activity (minutes per week and #times/wk resistance training) and improved quality of life (targeting physical function, social isolation, sexual functioning) compared to men in the control arm.

Aim 3. To explore the effects of the intervention program on blood pressure, blood lipids, fasting glucose, and biomarkers associated with comorbidities and carcinogenesis (i.e adiponectin, leptin, C-peptide, IGF-1, IGFBP-3, C-Reactive Protein, estradiol, testosterone and sex hormone binding globulin)

Hypothesis: Men in the guided arm will exhibit greater improvements in biomarkers associated with chronic disease and carcionogenesis compared to men in the self-guided control arm.

Men Moving Forward supports PC survivors in adopting physical activity and eating patterns that will improve their body composition, bolster QOL and reduce risk for comorbidities and, potentially, PC recurrence.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 200 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Participants will be randomized to either a guided or self-guided lifestyle intervention
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
• Actual Study Start Date: June 1, 2019
• Estimated Primary Completion Date: June 30, 2023
• Estimated Study Completion Date: June 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Immediate Lifestyle program; The Intervention will be conducted in cohorts of 15-20. We anticipate there will be 5-6 cohorts over the course of the study. Men assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies, the second hour will be supervised exercise with strength training. The second weekly session will be a one-hour supervised exercise session with strength training. Men will also receive 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.	Behavioral: Immediate Guided Lifestyle Program Intervention; The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
Waitlist Control; In the waitlist control arm, the men will not receive any intervention for 16-weeks. After the 16-week assessment, men randomized to this arm will crossover to the intervention arm.	Behavioral: Immediate Guided Lifestyle Program Intervention; The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.

Outcome Measures

Primary Outcome Measures :

1. Change in body composition [ Time Frame: Change from Baseline to 4 month ]
   Ratio of percent lean mass to percent adiposity as measured by DEXA. More lean mass and less adiposity is favorable.
2. Change in body composition [ Time Frame: Change from Baseline to 12 month ]
   Ratio of percent lean mass to percent adiposity as measured by DEXA. More lean mass and less adiposity is favorable.
3. Increase in intake of fruits and vegetables [ Time Frame: Change from Baseline to 4 month ]
   VioScreen's dietary analysis of self reported food consumption
4. Increase in intake of fruits and vegetables [ Time Frame: Change from Baseline to 12 month ]
   VioScreen's dietary analysis of self reported food consumption
5. Decrease of intake of red meat/processed meat [ Time Frame: Change from Baseline to 4 month ]
   VioScreen's dietary analysis of self reported food consumption
6. Decrease of intake of red meat/processed meat [ Time Frame: Change from Baseline to 12 month ]
   VioScreen's dietary analysis of self reported food consumption
7. Increase in levels of physical activity- minutes per week [ Time Frame: Change from Baseline to 4 month ]
   Change of ActiGraph monitored activity
8. Increase in levels of physical activity- minutes per week [ Time Frame: Change from Baseline to 12 month ]
   Change of ActiGraph monitored activity
9. Increase in levels of physical activity- #times per week [ Time Frame: Change from Baseline to 4 month ]
   Change of ActiGraph monitored activity
10. Increase in levels of physical activity- #times per week [ Time Frame: Change from Baseline to 12 month ]
    Change of ActiGraph monitored activity
11. Increase in resistance training- Lower extremity strength [ Time Frame: Change from Baseline to 4 month ]
    Isokinetic dynamometer (HUMAC Norm, Stoughton, MA).
12. Increase in resistance training- Lower extremity strength [ Time Frame: Change from Baseline to 12 month ]
    Isokinetic dynamometer (HUMAC Norm, Stoughton, MA).
13. Increase in resistance training- Handgrip strength [ Time Frame: Change from Baseline to 4 month ]
    Takei 5401 Hand Grip Digital Dynamometer
14. Increase in resistance training- Handgrip strength [ Time Frame: Change from Baseline to 12 month ]
    Takei 5401 Hand Grip Digital Dynamometer
15. Increase in resistance training- Strength and endurance [ Time Frame: Change from Baseline to 4 month ]
    30-Second Chair Stand (Sit to Stand)
16. Increase in resistance training- Strength and endurance [ Time Frame: Change from Baseline to 12 month ]
    30-Second Chair Stand (Sit to Stand)
17. Change in Quality of Life- PROMIS [ Time Frame: Change from Baseline to 4 month ]
    PROMIS T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. PROMIS measures physical function, depression, anxiety, fatigue, sleep disturbance, social roles, pain interference, social isolation, cognitive function, support, self-efficacy and sexual function.
18. Change in Quality of Life-PROMIS [ Time Frame: Change from Baseline to 4 month ]
    PROMIS T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. PROMIS measures physical function, depression, anxiety, fatigue, sleep disturbance, social roles, pain interference, social isolation, cognitive function, support, self-efficacy and sexual function.
19. Change in Urban life stress inventory- Crisys [ Time Frame: Change from Baseline to 4 month ]
    Measure change of mean in positive/negative/neutral and resolved/ongoing
20. Change in Urban life stress inventory-Crisys [ Time Frame: Change from Baseline to 12 month ]
    Measure change of mean in positive/negative/neutral and resolved/ongoing
21. Changes in Blood Pressure [ Time Frame: Change from Baseline to 4 month ]
    Participants blood pressure will be measured using a digital, automated unit
22. Change in Blood Pressure [ Time Frame: Change from Baseline to 12 month ]
    Participants blood pressure will be measured using a digital, automated unit
23. Change in Biomarkers- Hemoglobin [ Time Frame: Change from Baseline to 4 month ]
    Hemoglobin blood tests measured by Wisconsin Diagnostic Laboratory
24. Change in Biomarkers-Hemoglobin [ Time Frame: Change from Baseline to 12 month ]
    Hemoglobin blood tests measured by Wisconsin Diagnostic Laboratory
25. Change in Biomarkers- A1C [ Time Frame: Change from Baseline to 4 month ]
    A1C blood tests measured by Wisconsin Diagnostic Laboratory
26. Change in Biomarkers- A1C [ Time Frame: Change from Baseline to 12 month ]
    A1C blood tests measured by Wisconsin Diagnostic Laboratory
27. Change in Biomarkers- Hormones-Testosterone [ Time Frame: Change from Baseline to 4 month ]
    Testosterone blood test measured by Wisconsin Diagnostic Laboratory
28. Change in Biomarkers- Hormones-Testosterone [ Time Frame: Change from Baseline to 12 month ]
    Testosterone blood test measured by Wisconsin Diagnostic Laboratory
29. Change in Biomarkers- Hormones- Estradiol [ Time Frame: Change from Baseline to 4 month ]
    Estradiol blood test measured by Wisconsin Diagnostic Laboratory
30. Change in Biomarkers- Hormones- Estradiol [ Time Frame: Change from Baseline to 12 month ]
    Estradiol blood test measured by Wisconsin Diagnostic Laboratory
31. Change in Biomarkers- Hormones- SHBG [ Time Frame: Change from Baseline to 4 month ]
    SHBG blood test measured by Wisconsin Diagnostic Laboratory
32. Change in Biomarkers- Hormones- SHBG [ Time Frame: Change from Baseline to 12 month ]
    SHBG blood test measured by Wisconsin Diagnostic Laboratory
33. Change in Biomarkers-Adipokines- Leptin [ Time Frame: Change from Baseline to 4 month ]
    Leptin blood test measured by Wisconsin Diagnostic Laboratory
34. Change in Biomarkers-Adipokines- Leptin [ Time Frame: Change from Baseline to 12 month ]
    Leptin,blood test measured by Wisconsin Diagnostic Laboratory
35. Change in Biomarkers-Adipokines-Adiponectin [ Time Frame: Change from Baseline to 4 month ]
    Adiponectin blood test measured by Wisconsin Diagnostic Laboratory
36. Change in Biomarkers-Adipokines-Adiponectin [ Time Frame: Change from Baseline to 12 month ]
    Adiponectin blood test measured by Wisconsin Diagnostic Laboratory
37. Change in Biomarkers-Inflammation- IL-6 [ Time Frame: Change from Baseline to 4 month ]
    IL-6 blood test measured by Wisconsin Diagnostic Laboratory
38. Change in Biomarkers-Inflammation- IL-6 [ Time Frame: Change from Baseline to 12 month ]
    IL-6 blood test measured by Wisconsin Diagnostic Laboratory Wisconsin
39. Change in Biomarkers-Inflammation-TNFα [ Time Frame: Change from Baseline to 4 month ]
    TNFα blood test measured by Wisconsin Diagnostic Laboratory
40. Change in Biomarkers-Inflammation-TNFα [ Time Frame: Change from Baseline to 12 month ]
    TNFα blood test measured by Wisconsin Diagnostic Laboratory
41. Change in Biomarkers-Insulin Resistance-C-Peptide [ Time Frame: Change from Baseline to 4 month ]
    C-Peptide blood test measured by Wisconsin Diagnostic Laboratory
42. Change in Biomarkers-Insulin Resistance- C-Peptide [ Time Frame: Change from Baseline to 12 month ]
    C-Peptide blood test measured by Wisconsin Diagnostic Laboratory
43. Change in Biomarkers-Insulin Resistance-IGF-1 [ Time Frame: Change from Baseline to 4 month ]
    IGF-1 blood test measured by Wisconsin Diagnostic Laboratory
44. Change in Biomarkers Insulin Resistance-IGF-1 [ Time Frame: Change from Baseline to 12 month ]
    IGF-1 blood test measured by Wisconsin Diagnostic Laboratory

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Male Prostate Cancer study participants
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age 18 years and older
• Self-identify as Black or African American
• Diagnosed with non-metastatic Prostate Cancer (cancer that has NOT spread elsewhere in the body)
• Completed all treatments (including Androgen Deprivation Therapy) at least six months prior to enrollment
• BMI > 25 kg/m2
• Able to participate in moderate physical activity as assessed by healthcare provider
• Exercise less than the ACS recommended guideline of 150 min/week or 30 min/day.
• Fruit and vegetable consumption is less than 5 servings each day.
• Lift Weights or engage in strength training less than twice a week.
• Can walk continuously for 5 minutes without stopping because of pain or shortness of breath.
• Have access to a mobile phone
• Approval from Primary Care Provider/Medical Oncologist
• Available to attend intervention

Exclusion Criteria:

• • Does not meet the Inclusion Criteria

Contacts and Locations

Contacts

Contact: Jo Bergholte, MLIS; 414-805-6990; jbergholte@mcw.edu

Contact: Kathleen Jensik, MSW; 414-955-2114; kjensik@mcw.edu

Locations

United States, Wisconsin

Medical College of Wisconsin; Recruiting

Milwaukee, Wisconsin, United States, 53226

Contact: Tina Johnson 414-955-4095 jojohnso@mcw.edu

Contact: Kathleen Jensik, MSW 414-955-2114 kjensik@mcw.edu

Principal Investigator: Melinda Stolley, PhD

Sponsors and Collaborators

Medical College of Wisconsin

Loyola University Chicago

Marquette University

University of Illinois at Chicago

More Information

• Responsible Party: Melinda Stolley, Associate Director for Cancer Prevention and Control, Medical College of Wisconsin
• ClinicalTrials.gov Identifier: NCT03971591
• Other Study ID Numbers: PRO00031416
• First Posted: June 3, 2019
• Last Update Posted: October 13, 2022
• Last Verified: October 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Prostatic Diseases